Alterity Therapeutics (NASDAQ:ATHE) Stock Rating Lowered by Benchmark

Alterity Therapeutics (NASDAQ:ATHE) was downgraded by stock analysts at Benchmark from a “speculative buy” rating to a “hold” rating in a report issued on Monday, MarketBeat.com reports.

Separately, Maxim Group raised their target price on shares of Alterity Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday.

Alterity Therapeutics Price Performance

Shares of ATHE stock opened at $4.80 on Monday. The company’s fifty day simple moving average is $2.78 and its 200-day simple moving average is $1.83. Alterity Therapeutics has a 52 week low of $1.00 and a 52 week high of $5.87.

Institutional Investors Weigh In On Alterity Therapeutics

An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC raised its stake in Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 31,883 shares of the company’s stock after purchasing an additional 8,100 shares during the period. HB Wealth Management LLC owned 0.44% of Alterity Therapeutics worth $110,000 as of its most recent SEC filing. Institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.